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Abstract
Background
Huntington’s disease is an inherited neurodegenerative disorder characterised by motor,
cognitive and psychiatric disturbances. Patients exhibit other symptoms including sleep
and mood disturbances, muscle atrophy and weight loss which may be linked to hypotha-
lamic pathology and dysfunction of hypothalamo-pituitary axes.
Methods
We studied neuroendocrine profiles of corticotropic, somatotropic and gonadotropic
hypothalamo-pituitary axes hormones over a 24-hour period in controlled environment in
15 healthy controls, 14 premanifest and 13 stage II/III Huntington’s disease subjects. We
also quantified fasting levels of vasopressin, oestradiol, testosterone, dehydroepiandroster-
one sulphate, thyroid stimulating hormone, free triiodothyronine, free total thyroxine, prolac-
tin, adrenaline and noradrenaline. Somatotropic axis hormones, growth hormone releasing
hormone, insulin-like growth factor-1 and insulin-like factor binding protein-3 were quantified
at 06:00 (fasting), 15:00 and 23:00. A battery of clinical tests, including neurological rating
and function scales were performed.
Results
24-hour concentrations of adrenocorticotropic hormone, cortisol, luteinizing hormone and
follicle-stimulating hormone did not differ significantly between the Huntington’s disease
group and controls. Daytime growth hormone secretion was similar in control and Hunting-
ton’s disease subjects. Stage II/III Huntington’s disease subjects had lower concentration of
post-sleep growth hormone pulse and higher insulin-like growth factor-1:growth hormone
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ratio which did not reach significance. In Huntington’s disease subjects, baseline levels of
hypothalamo-pituitary axis hormones measured did not significantly differ from those of
healthy controls.
Conclusions
The relatively small subject group means that the study may not detect subtle perturbations
in hormone concentrations. A targeted study of the somatotropic axis in larger cohorts may
be warranted. However, the lack of significant results despite many variables being tested
does imply that the majority of them do not differ substantially between HD and controls.
Introduction
Huntington´s disease (HD) is an inherited neurodegenerative disease, caused by a CAG triplet
repeat expansion in the gene encoding huntingtin [1]. Classical features of HD include motor
manifestations, cognitive and psychiatric symptoms [2]. However, these are not the sole manifesta-
tions in HD, and disruption of circadian rhythms [3–6], alterations in sleep patterns [7–9], altered
glucose homeostasis [10–13], muscle atrophy [14] and weight loss [15–17] may also impact on the
quality of life of the patients and can precede motor symptoms by many years. Extensive research
in animal models of HD [18,19] and HD patients [20–26] suggests that these symptoms could be
linked to progressive hypothalamic pathology and changes in the neuroendocrine systems.
The hypothalamus exerts control over many bodily functions via three major outputs: auto-
nomic, endocrine and behavioural systems. It acts as the coordinating centre for the neuroen-
docrine system. Hypothalamic endocrine efferent output is mediated through the
hypothalamic pituitary axes [27,28], regulating the function of the thyroid gland, the adrenal
gland, and the gonads, and, thereby, the circulating levels of growth hormone, thyroid hor-
mones, cortisol, testosterone and oestrogens [29,30].
Alterations of the hypothalamic-pituitary-adrenal (HPA) axis have been shown in HD
patients [24,26,31,32] and in HD mouse models [19]. Interestingly, increased cortisol levels
[22–24,26] can cause symptoms that are common in HD patients such as depression [33–36],
skeletal muscle atrophy, altered glucose tolerance and memory impairment [37].
Since the thyrotropic axis is involved in the regulation of body weight and metabolism [38],
which are affected in HD [15], several studies have evaluated hypothalamic-pituitary-thyroid
(HPT) axis function in patients with HD, with conflicting results [24,39–41].
The hypothalamic-pituitary-gonadal (HPG) axis has also been shown altered in HD mice
[42,43] and in men with HD, where reduced testosterone levels have been shown to be linked
to disease severity [24,44]. Gonadotropic axis hormones have not been carefully investigated in
female HD patients.
We conducted a study to analyse the corticotropic, thyrotropic, gonadotropic, somatotropic
and lactotropic axes in detail over a 24-hour period in a controlled environment, using cohorts
of premanifest and moderate HD subjects and healthy controls.
Methods
Participants
Patients were eligible for enrolment if they were 18 years of age or older, had completed either
a predictive or diagnostic genetic test for HD (CAG repeat40). Patients were excluded from
Hypothalamo-Pituitary Axes in HD
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the study if they had: pre-existent endocrine disease, central nervous system disorder other
than HD, history of alcohol or drug abuse, treatment with corticosteroids, phenothiazine anti-
emetics, antipsychotic medication (including neuroleptics, SSRI drugs), or hypnotic drugs for
preceding 6 months, night shift working and weight change in the preceding 6 months. Controls
were recruited principally from the partners, spouses, or carers of the HD group with no clinical
evidence or family history of HD and the same exclusion criteria applied. Fifteen healthy con-
trols, 14 gene carriers (premanifest HD) and 13 stage II/III HD patients were enrolled into a
study analysing neuroendocrine factors. The study was conducted at the Royal Free London
NHS Foundation Trust. Participants were recruited through the HDMultidisciplinary Clinic at
the National Hospital for Neurology and Neurosurgery, London, UK. Written informed consent
was obtained from all subjects. The study protocol was approved by the joint UCL/UCLH ethics
committee and was conducted in accordance with the Declaration of Helsinki.
Clinical protocol
Study subjects underwent to a 24-hour inpatient stay in the hospital. Subjects were advised to
observe their usual bedtime, wake time, and mealtime patterns in the week preceding the
study. During the study, subjects could walk freely or watch television, but not fall asleep or
snack outside scheduled mealtimes. A cannula was inserted 60 minutes before the start of
blood sampling at 14:00 hours. Sampling was performed through a long line to minimise sleep
disruption. The aim for female subjects was to be sampled, where possible, at the midpoint of
their menstrual cycle in order to standardise hormone analysis.
The following pituitary axis hormones were assayed: vasopressin, corticotropic-axis hor-
mones (adrenocorticotropic hormone [ACTH] and cortisol), somatotropic-axis hormones
(growth hormone releasing hormone [GHRH], growth hormone [GH], insulin-like growth
factor-1 [IGF-1], and insulin-like factor binding protein-3 [IGF-BP3]), gonadotropic axis hor-
mones (luteinizing hormone [LH], follicle-stimulating hormone [FSH], oestradiol and testos-
terone in female and male), thyrotropic axis hormones (thyroid stimulating hormone [TSH],
free triiodothyronine [fT3], and free total thyroxine [fT4]) and lactotropic axis hormone (pro-
lactin). Samples for ACTH, cortisol, GH, LH and FSH analysis were taken hourly from 14:00
on day 1 until 13:00 on day 2. Plasma for catecholamines (adrenaline, noradrenaline), vaso-
pressin, fT3, fT4 and TSH, prolactin, total testosterone, oestradiol and dehydroepiandrosterone
sulphate (DHEAS) analysis was drawn at 06:00 on day 2 after an overnight fast. Plasma for
GHRH, IGF-1and IGF-BP3 was taken at 06:00, 15:00 and 23:00. During the study, urine was
collected over 24 hours for the determination of cortisol concentration.
Clinical assessment and HD rating scales were performed by neurologist with expertise in
HD. The Unified Huntington’s Disease Rating Scale (UHDRS), motor section (MS), Total
Functional Capacity (TFC), and Functional activity (FA), were assessed. Cognitive function
was assessed by Stroop Test Evaluation Colour Naming (STECN), Stroop Test Evaluation
Word Reading (STEWR), Stroop Test Evaluation Interference (STEI), Symbol Digit Test
(SDT) and Verbal Fluency Test (VFT). Problem behaviours assessment (PBA) was also used
and behavioural score was calculated [45–47]. For HD gene carriers, subjects who were
scored as 4 on the diagnostic confidence score of the Motor scale (motor abnormalities>99%
likely to be due to HD) were classed as affected and those who scored 0 or 1 were classed as
premanifest.
Sample collection and analysis
Assays were performed according to the manufacturer’s instructions for the relevant kit. Blood
for the analysis of serum cortisol, GH, LH, FSH, oestradiol, DHEAS, testosterone, prolactin
Hypothalamo-Pituitary Axes in HD
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and thyroid hormones were collected in BD Vacutainer Serum Separation Tubes while blood
for ACTH analysis was collected into EDTA containing tubes. Plasma samples for catechol-
amines and vasopressin were collected in BD Vacutainer Lithium Heparin tubes. Specimens
for ACTH analysis were immediately placed on ice and were centrifuged at 2500 rotations per
minute (rpm), at 4°C, for 5 minutes, soon after venesection. Specimens for catecholamines
were also spun immediately after collection while all the other specimens were kept at room
temperature and centrifuged within 60 minutes of sampling at 2500 rpm, at 4°C, for 5 minutes.
Plasma and serum samples were immediately frozen on dry ice and stored at ‐80°C prior to
analysis.
24 hour urine samples for free cortisol measurement were collected into plain containers,
the bottles were weighed and the total urine volume recorded. 600 μL aliquots of urine under-
went liquid-liquid extraction with 3 mL dichloromethane. 1.5 mL of the non-polar layer was
transferred into glass boiling tubes and heated at 50°C until dry. The samples were reconsti-
tuted in 300 μL Elecsys Universal Diluent (Roche) and cortisol measured using the assay
described below. The 24 hour excretion values were calculated by multiplying the cortisol con-
centration by the 24 hour urine volume.
Serum IGF-1, IGF-BP3 and GHRH were measured in duplicate by enzyme-linked immuno-
sorbent assays (R&D Systems Europe, Ltd. Abingdon, UK). Concentrations of cortisol (mea-
suring range (MR): 0.5–1750 nmol/L), FSH (MR: 0.100–200 mIU/mL), LH (MR: 0.100–200
mIU/mL), FT3 (MR: 0.40–50.00 pmol/L), FT4 (MR: 0.3–100 pmol/L), TSH (MR: 0.005–
100 μIU/mL), prolactin (MR: 1.00–10000 μIU/mL), total testosterone (MR: 2.50–1500 ng/dL),
DHEAS (MR: 0.003–27.0 μmol/L) and oestradiol (MR: 0.003–27.0 μmol/L) were determined
by electrochemiluminescent immunoassay on a Roche Modular E170 autoanalyser. Serum GH
and ACTH were quantified using chemiluminescent immunoassays on a Siemens Immulite
Analyser (GHMR: 0.01–40.00 μg/L, ACTHMR: 5–1250 pg/mL). Plasma catecholamines were
quantified by reverse phase partition high performance liquid chromatography HPLC.
Statistical analysis
Results are expressed as mean ± standard deviation (SD) or median (minimum-maximum).
Disease burden score, which correlates with and is an indicator of the severity of neuropathol-
ogy of HD, was calculated for each HD gene carrier using the formula [CAG repeat length –
35.5} x age [48]. Inter-group differences were assessed by linear regression of the relevant
variable (or its log if necessary for normality) on disease group and adjusting for age and gen-
der, or (in the absence of normality or log-normality) by using a permutation test after Freed-
man and Lane [49]. This latter test is based on permutations of the residuals calculated under
the reduced model of the full linear regression one, with the same predictor variables [50]. For
relevant sex hormones, where there are marked differences by gender, analyses were performed
separately by gender. All tests were two-tailed and significance level was set at p<0.05. There
was no formal adjustment for multiple testing, since all hypotheses tested are interesting in
their own right, although the number of comparisons made is borne in mind in the interpreta-
tion of any significant results [51]. Statistical analyses were performed using SPSS for Windows
(release 16.0, SPSS, Inc., Chicago, IL) and using Stata (release 13: StataCorp Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP).
Fourier Transformation (FT) analysis was utilised to measure spectral power of ACTH, cor-
tisol, GH and LH oscillations, enabling analysis of the strength/power of hormonal oscillations
at different frequencies [52,53] (http://ora.ox.ac.uk/objects/ora:2356). Signal–noise ratio was
improved using a 3-point moving average and any trend in the data was removed by a differ-
ence + mean regression. Data were analysed using the EASY-TSA program (Oxford University,
Hypothalamo-Pituitary Axes in HD
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UK: Nathan.hill@phc.ox.ac.uk) [53]. Comparisons between waveforms of time series analysis
were performed by probability of SEM at any discrete time-point overlapping the SEM of the
comparative group.
Results
The demographic data and clinical characteristics of the healthy controls, premanifest, and
stage II/III HD patients are reported in Table 1. This shows some differences between groups,
particularly in age, where median age is lower in the premanifest group, and older in the
moderate/ severe Huntington group, compared to controls. For clinical ratings there is some
overlap in range for premanifest and manifest HD groups. This reflects the fact that HD
pathology is a continuum and although the diagnostic confidence score identifies the groups
there is not a strict dichotomy for the two groups. For further discussion of the diagnosis and
classification of HD see review by Ross et al [54]. Three patients with stage II/III HD were
excluded on screening as they were taking neuroleptic medication. Table 2 presents hormone
concentrations.
Corticotropic axis
In all three groups the 24-hour profiles of ACTH and cortisol display a typical pattern with
early morning peak concentrations and declining levels throughout daytime, with lowest values
around midnight (Fig 1A and 1B). There was an elevation of ACTH (Fig 1A) and cortisol
(Fig 1B) levels during late sleep in all three groups.
Relative FT analysis of ACTH levels showed an initial pulsatility at 132 minutes for all
groups (Fig 1C) (oscillatory power: control 0.57, SEM 0.10; premanifest HD 0.50, SEM 0.10;
stage II/III HD 0.57, SEM 0.09) with a further periodicity peak at 440 minutes (oscillatory
power: control 1.0, SEM 0.17; premanifest HD 0.76, SEM 0.17; stage II/III HD 0.85, SEM 0.23).
Overall between-group comparison at both 132 and 440 minutes did not reach statistical signif-
icance. For cortisol (Fig 1D), initial dominant pulsatility was at 132 minutes (oscillatory power:
Table 1. Demographic characteristics and clinical features of controls, pre-manifest and stage II/III
HD cohorts. Data presented as median (range).
Disease stage Controls Pre-manifest HD Stage II/III HD
Number of subjects 15 14 13
Age 54 (29–69) 45 (31–58) 58 (42–70)
Female: Male 6:9 9:5 5:8
BMI 25 (20–37) 27 (23–39) 26 (20–33)
CAG - 42 (40–47) 42 (42–47)
Disease burden score - 299 (207–434) 410 (273–702)
Functional Assessment 25 25 (21–25) 21 (11–24)
UHDRS Total Functional Capacity 13 13 (12–13) 9 (5–12)
UHDRS Motor Score 0 0 (0–11) 38 (10–65)
STECN 82 (60–93) 71 (47–91) 45 (30–81)
STEWR 100 (83–102) 96 (64–110) 57 (37–100)
STEI 45 (29–68) 42 (34–52) 24 (20–44)
SDT 51 (42–65) 52 (37–62) 31 (17–50)
VFT 48 (30–66) 41 (26–70) 27 (12–58)
CS 322 (276–359) 298 (225–369) 182 (133–308)
PBA 2 (0–10) 8 (2–31) 21 (5–55)
doi:10.1371/journal.pone.0138848.t001
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Table 2. Hormone levels in control, premanifest and stage II/III HD cohorts. Data are presented as Mean ±SD for normally distributed data and as
median [minimum–maximum] for skewed data.
Axis Control Premanifest HD Stage II/III HD p
Corticotropic axis
ACTH, 24 h, ng/L 11.4 [7.4–23.5] 13.0 [7.7–28.0] 13.4 [7.1–31.4] 0.63L
Cortisol, 24 h, nmol/L 232 [165–636] 224 [100–498] 212 [97–363] 0.54L
Cortisol, urine, nmol/24 h 179 [58–758] 136 [35–434] 121 [50–295] 0.63L
Cortisol: ACTH ratio, 24 h 79200 [7800–802000] 63300 [9100–489300] 65100 [10600–317200] 0.35L
Cortisol: ACTH ratio, evening 93600 [37000–705200] 70800 [25300–226900] 60800 [22900–142500] 0.06L
Vasopressin, pg/ml 0.84 [0.56–1.92] 0.79 [0.59–1.49] 0.77 [0.53–1.68] 0.89LP
Somatotropic axis
GH, μg/L
24 h 0.7 [0.1–5.7] 0.7 [0.1–1.6] 0.4 [0.1–1.7] 0.48LP
Post-sleep 2.1 [0.2–8.4] 1.1 [0.2–3.5] 0.3 [0.1–2.2] 0.09L
GHRF, ng/ml
06:00 0.77 ± 0.24 0.76 ± 0.16 0.71 ± 0.23 0.7
15:00 0.76 ± 0.18 0.80 ± 0.38 0.82 ± 0.19 0.83P
23:00 0.78 ± 0.17 0.79 ± 0.16 0.72 ± 0.18 0.29
IGF-1, ng/ml
06:00 106 [76–154] 121 [69–218] 90 [66–232] 0.88L
15:00 128 [77–154] 110 [65–230] 109 [69–250] 0.70L
23:00 107 [75–161] 113 [64–257] 106 [76–207] 0.997L
IGF-BP3, ng/ml
06:00 2590 ± 400 2481 ± 584 2308 ± 531 0.38P
15:00 2823 ± 575 2444 ± 407 2625 ± 553 0.08P
23:00 2501 ± 557 2499 ± 358 2254 ± 494 0.50P
IGF-1:GH ratio
06:00 801 [77–2194] 352 [11–2211] 987 [49–1642] 0.80LP
15:00 744 [31–3070] 613 [20–2451] 1389 [17–3043] 0.96LP
23:00 271 [15–1505] 300 [20–5132] 1149 [26–2630] 0.23L
Gonadotropic axis
LH, U/L
Female, 24 h 14.0 [1.6–46.5] 7.2 [0.1–30.9] 21.8 [3.2–32.1] 0.87L
Male, 24 h 5.2 [2.5–7.8] 5.0 [3.1–6.1] 4.9 [3.4–6.0] 0.98L
FSH, U/L
Female, 24 h 46.1 [1.5–140.1] 5.0 [0.6–278.9] 32.9 [7.3–65.3] 0.88L
Male, 24 h 5.9 [2.4–12.0] 5.5 [3.1–6.0] 5.3 [1.8–7.4] 0.53L
Testosterone, nmol/L
Females 0.73 ± 0.27 0.84 ± 0.38 0.50 ± 0.27 0.6
Males 15.5 ± 7.7 15.5 ± 5.3 16.8 ± 4.6 0.59
Oestradiol, pmol/L
Females 50 [50–1432] 171 [50–791] 84 [56–218] 0.89LP
Males 109 [50–156] 100 [71–334] 121 [50–221] 0.57L
DHEAS, umol/L 4.81 ± 2.21 4.12 ± 1.92 2.77 ± 2.31 0.04
Females 3.7 ± 1.2 3.3 ± 1.3 2.1 ± 1.4 0.24
Males 5.6 ± 2.4 6.0 ± 1.8 3.2 ± 2.7 0.17
Lactotropic axis
Prolactin, mU/L
Females 360 ± 125 432 ± 195 461 ± 257 0.33P
(Continued)
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control 7.5, SEM 0.88; premanifest HD 6.31, SEM 1.16; stage II/III HD 7.04, SEM 1.17) with a
further periodicity peak at 440 minutes (oscillatory power: control 16.42, SEM 3.22; premani-
fest HD 13.94, SEM 2.02; stage II/III HD 13.64, SEM 1.98) and again there was no significant
difference between groups.
Mean levels of ACTH and cortisol over 24 hours (Table 2) did not differ significantly
between groups, nor did 24-hour urinary cortisol. A comparison of cortisol to ACTH ratio for
the three groups (Fig 1E) also did not demonstrate any significant differences.
Vasopressin
Wemeasured baseline plasma levels of vasopressin. There was no significant difference in
plasma vasopressin levels between the groups.
Somatotropic axis
24-hour profile of GH, and baseline levels of GHRH (a hormone that stimulates GH secretion
from the pituitary), IGF-1 and IGF-BP3 are shown in Fig 2A and Table 2. In all three groups,
the 24-hour profile of GH plasma levels consisted of low levels interrupted by bursts of secre-
tion (Fig 2A). It has been reported that GH is released in a pulsatile manner with the largest
and most reproducible pulse occurring shortly after sleep onset [55]. Since the subjects in this
study retired to bed at 22:00, we calculated the mean GH concentration during the first half of
the night (22:00–01:00). Mean concentrations of 24 hour and post-sleep GH were lower in the
stage II/III HD patients but analysis corrected for age and gender did not demonstrate a signifi-
cant difference (Table 2).
Relative FT of GH levels showed an initial pulsatility at 132 minutes for all groups (Fig 2B)
(oscillatory power: control 0.14, SEM 0.04; premanifest HD 0.07, SEM 0.01; stage II/III HD
0.14, SEM 0.03) with a further periodicity peak at 440 minutes (oscillatory power: control 0.34,
SEM 0.11; premanifest HD 0.05, SEM 0.01; stage II/III HD 0.18, SEM 0.05). Overall between-
group comparison at 132 minutes did not reach statistical significance.
We also evaluated other variables of the somatotropic axis hormones, including GHRH,
IGF-1 and IGF-BP3 at 06:00 (fasting), 15:00 and 23:00. There was no significant difference in
plasma GHRH, IGF-1, IGF-BP3 or the IGF-1:GH ratio among the three groups at the three
time-points we sampled (Table 2).
Table 2. (Continued)
Axis Control Premanifest HD Stage II/III HD p
Males 245 ± 98 247 ± 47 235 ± 60 0.98
Thyrotropic axis
TSH, mU/L 2.61 ± 1.34 3.23 ± 3.01 1.98 ± 1.10 0.81
fT3, pmol/L 4.48 ± 0.70 5.04 ± 0.64 4.91 ± 0.59 0.08
fT4, pmol/L 14.7 ± 2.19 15.4 ± 2.31 15.5 ± 2.2 0.62
fT4:fT3 ratio 3.32 ± 0.42 3.09 ± 0.41 3.21 ± 0.54 0.52
Catecholamines
Adrenaline, nmol/L 0.46 ± 0.17 0.36 ± 0.17 0.42 ± 0.21 0.29
Noradrenaline, nmol/L 1.86 ± 0.71 2.16 ± 0.63 1.89 ± 0.80 0.64
P-value = p-value from linear regression of speciﬁed variable on age and gender (or else by gender as indicated), L indicates that logs were taken of the
speciﬁed variable prior to linear regression; P indicates Freedman and Lane permutation tests were performed to account to non-normality, LP indicates
Freedman and Lane permutation tests were performed after taking logs of the speciﬁed variable. In all cases, age and gender were adjusted for.
doi:10.1371/journal.pone.0138848.t002
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Fig 1. Analysis of ACTH and cortisol in control, premanifest and stage II/III HD cohorts. A: Mean ACTH concentrations over 24 hour sampling period in
the three groups. B: Mean ACTH concentrations over 24 hour sampling period in the three groups. C: FT analysis of ACTH plotting strength/power (%)
against frequency (minutes) of ACTH oscillations for the three groups. D: FT analysis of cortisol plotting strength/power (%) against frequency (minutes) of
cortisol oscillations for the three groups. E: Mean molar cortisol:ACTH ratio over 24 hour sampling period in the three groups.
doi:10.1371/journal.pone.0138848.g001
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Gonadotropic axis
We assessed the 24-hour profiles of gonadotropic axis hormones LH and FSH, as well as
fasting levels of testosterone, oestradiol and DHEAS in serum from control, premanifest and
stage II/III HD subjects. Since gender has a major effect on the levels of gonadotropic axis hor-
mones, the data for all gonadotropic hormones was analysed separately for males and females.
In males, the pattern of LH release in all three groups exhibited episodic pulses with large
inter-individual variability and no obvious diurnal variation (Fig 3B). The 24-hour FSH profile
in males was similar in all three groups with very low levels throughout the day, without any
diurnal variation (Fig 4B).
Although the aim for female subjects was to be sampled, where possible, at the midpoint of
their menstrual cycle in order to standardise hormone analysis, this was not always the case.
The young female participants were using different contraceptive methods (pill, implant or
injections). Other female participants were either at a premenopausal stage with irregular men-
strual cycle or menopausal. Therefore, the 24-hour LH and FSH profiles for female subjects
may not be very informative. However, it can be observed that the LH and the FSH 24-hour
Fig 2. Analysis of GH in control, premanifest and stage II/III HD cohorts. A: Mean GH concentrations
over 24 hour sampling period in the three groups. B: FT analysis of GH plotting strength/power (%) against
frequency (minutes) of GH oscillations for the three groups.
doi:10.1371/journal.pone.0138848.g002
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profiles do not differ between control, premanifest HD and stage II/III HD females (Figs 3A
and 4A, respectively).
Relative FT analysis of LH release showed an initial pulsatility at 132 minutes (Fig 3C)
(oscillatory power: control 0.16, SEM 0.02; premanifest HD 0.21, SEM 0.03; stage II/III HD
0.17, SEM 0.05) with a further periodicity peak at 440 minutes (oscillatory power: control 0.25,
SEM 0.04; premanifest HD 0.26, SEM 0.07; stage II/III HD 0.22, SEM 0.05). Overall between-
group comparison at 132 and 440 minutes did not reach statistical significance.
Relative FT analysis of FSH release showed oscillatory power was supressed in both the con-
trol and stage II/III HD group in comparison to the premanifest HD group although this did
not reach statistical significance. There was an initial pulsatility at 147 minutes for all groups
(Fig 4C) (oscillatory power: control 0.17, SEM 0.09; premanifest HD 0.14, SEM 0.07; stage II/
III HD 0.07 SEM 0.03) with a further periodicity peak in the premanifest HD group only at 660
minutes (oscillatory power: 2.58, SEM 2.43). Overall between-group comparison at 147 and
660 minutes periodicity did not reach statistical significance.
There was no significant difference in oestradiol or testosterone levels between the three
groups in males or females (Table 2). Linear regression of disease group adjusting for age and
sex suggested a significant difference in fasting DHEAS levels (males and females combined,
F2,36 = 3.51, p 0.04); the means observed in the three groups shows that means were substan-
tially lower in stage II/III HD, than in controls (with mean in premanifest HD nearer to those
in controls). Analysis of DHEAS concentrations in male and female subjects separately showed
lower levels in stage II/III disease groups but no significant difference in comparison with con-
trols/premanifest HD groups (Table 2).
Lactotropic axis
Fasting serum levels of prolactin were not significantly different between the three study
cohorts (Table 2).
Thyrotropic axis
Fasting concentrations of thyrotropic axis hormones TSH, fT3 and fT4 and ratio of fT4:fT3 in
control, premanifest HD and stage II/III HD serum showed that TSH and fT4 were similar
across the three groups (Table 2), and linear regression analysis adjusting for age and gender
showed was no significant between group difference.
Catecholamines
Analysis of fasting plasma concentrations of catecholamines (adrenaline and noradrenaline)
did not demonstrated significant differences between the groups (Table 2).
Discussion
Huntington’s disease (HD) is a devastating neurodegenerative disorder for which the underlying
pathophysiologic mechanisms affecting the brain and other organs remain unclear. Analyses of
peripheral tissues from HD patients suggest that the molecular mechanisms by which mutated
huntingtin leads to cell dysfunction may be similar with those in the central nervous system [56].
The hypothalamus is an important site for pathology in HD. MRI studies have reported
hypothalamic atrophy in early stage HD patients as well as in transgenic HDmice [57–61].
Grey matter alterations in the hypothalamus are among the earliest features detected in HD
[62]. Microglial activation and dopamine D2 receptor reduction occur in the hypothalamic
region before onset of motor symptoms in HD gene carriers [63]. Furthermore, reduction in
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Fig 3. Analysis of LH in control, premanifest and stage II/III HD cohorts. A: Mean LH concentrations over
24 hour sampling period for female subjects in the three groups. B: Mean LH concentrations over 24 hour
sampling period for male subjects in the three groups. C: FT analysis of LH plotting strength/power (%)
against frequency (minutes) of LH oscillations for the three groups.
doi:10.1371/journal.pone.0138848.g003
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Fig 4. Analysis of FSH in control, premanifest and stage II/III HD cohorts. A: Mean FSH concentrations
over 24 hour sampling period for female subjects in the three groups. B: Mean FSH concentrations over 24
hour sampling period for male subjects in the three groups. C: FT analysis of FSH plotting strength/power (%)
against frequency (minutes) of FSH oscillations for the three groups.
doi:10.1371/journal.pone.0138848.g004
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orexin and loss of orexigenic neurons in the hypothalamus [64] and alterations in the HPA
axis have been shown in mouse models and patients with HD from an early disease stage
[15,19,24,26,64]. In bacterial artificial chromosome-mediated transgenic HD mice, a metabolic
phenotype including impaired glucose metabolism, insulin and leptin resistance was identified
that could be reversed by inactivation of mutant huntingtin in the hypothalamus [65].
A number of studies describe the effect of HD on the function of the hypothalamic-pituitary
axes. However, many of these report conflicting data and are difficult to compare due to meth-
odological issues such as different sampling times, analysis of patients with different disease
stages, inclusion of patients on medication that can affect hormone levels and fasting status. In
addition, with the exception of two studies that quantified vasopressin [66] and prolactin [67],
previous studies did not include premanifest HD gene carriers, and thus do not inform on the
state of the hypothalamic-pituitary axis early on in the disease course.
The strength of our study is that we included both premanifest and manifest HD gene carri-
ers, and have measured all the hormones in the same cohorts during a standardised day allow-
ing a direct comparison of hormone levels. Most previous studies applied a single or a few
baseline measurements, which is inadequate to assess either the pulsatile or circadian nature of
hormonal secretion, which are essential for normal hormone function [68]. We therefore per-
formed a detailed study of hormone secretory dynamics for the main hypothalamo-pituitary
axes in premanifest HD gene carriers, moderate HD patients and controls, to identify potential
HD state markers and inform on neuroendocrine abnormalities associated with HD. Due to
the intensive nature of this study on participants, cohort sizes were relatively small which
meant that small but biologically relevant changes could be overlooked.
Endocrine dysfunction in HD
There is evidence of abnormal function of the hypothalamus [64], pituitary gland [18], pancre-
atic islets [69,70] and adrenal glands [71] in animal models of HD, and to some extent in HD
patients. This may lead to dysfunction of the neuroendocrine system with downstream effects
on the metabolism of various cell types, including muscle cells and adipocytes, contributing to
peripheral tissue abnormalities observed in HD such as weight loss, energy metabolism
changes and altered glucose homeostasis [15–17].
Corticotropic axis
In the R6/2 mouse model increased adrenal cortex volume is seen from the age of 7 weeks [71]
and adrenal glands in 12-week-old mice contained intranuclear huntingtin-inclusions and
weighed 37% more than in WTmice [71]. This adrenal cortical hypertrophy may explain the
increased serum and urine corticosterone detected in R6/2 mice [19].
Corticotropic axis hormones ACTH and cortisol are released in pulsatile fashion with circa-
dian and ultradian rhythms governing their secretion [72–76]. Both are released approximately
hourly, with ACTH pulses preceding cortisol by approximately 10 minutes [74–76].
In HD, ACTH levels have been reported to be both increased [22] and unchanged [24].
Saleh et al found no significant difference between HD patients and controls in fasting morning
ACTH levels [24]. Heuser et al found significantly higher basal cortisol and ACTH concentra-
tions in HD patients than controls (at 19:00 hours), HD subjects had a tendency towards
blunted ACTH in response to CRH stimulation, but released normal amounts of cortisol, sug-
gesting dysregulation of the HPA axis [22].
We measured 24-hour secretion of ACTH and cortisol at hourly intervals and found no sig-
nificant difference between HD patients and controls in ACTH levels over 24 hours. In agree-
ment with Saleh et al, fasting levels of ACTH in the morning were not significantly different
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between HD patients and controls. In contrast to Heuser et al, we did not see increased ACTH
levels in the evening, although we did not include late stage HD patients, which could explain
why we do not see a significant increase in ACTH levels in the evening.
Previous studies have consistently reported that morning levels of cortisol are increased in
HD patients [23,24,26], whereas one study reported similar levels in the evening [21]. While
we found no significant difference in cortisol levels in HD subjects compared to controls over
24 hours, we observed higher cortisol levels in HD gene carrier in the morning but this was not
statistically significant. It is possible that we would need a higher number of subjects to repli-
cate the previously reported increase in morning cortisol.
Aziz et al measured cortisol levels during a 24-hour period at 10 minutes intervals [26] and
found that the total cortisol secretion rate and the amplitude of the diurnal cortisol profile were
significantly higher in early HD patients compared with controls. Transient awakenings inter-
rupting sleep consistently trigger pulses of cortisol secretion [77–79] and nocturnal arousals
increase morning cortisol levels [80]. It is therefore possible that the frequent sampling regime
contributed to the increased cortisol levels observed.
Studies have also shown that approximately 30% of patients with depression have increased
cortisol secretion [33,35,36,76] and this may be a factor contributing to increased levels seen in
other HD studies. We are not able to comment from our data as no participant had significant
depression.
Vasopressin
Vasopressin is released in a circadian pattern by neurons of the hypothalamus. It plays a key role
in homeostasis by the regulation of water retention through diuresis and thirst. Other roles of
vasopressin include regulation of temperature, blood pressure, social behaviour and sexual moti-
vation. Neuropathological analysis of the hypothalamus in post-mortem brain tissue has revealed
a reduction in the number of vasopressin-expressing neurons [81], and interestingly was also
present in a case of early stage HD who died of unrelated causes [82]. A previous study of post-
mortem hypothalamic tissue showed no significant difference in the number of vasopressin neu-
rons or vasopressin expression between controls and HD patients [83]. However, in the R6/2
mouse model the number of immunoreactive vasopressin neurons in the paraventricular nucleus
of the hypothalamus were significantly decreased, suggesting that the change in drinking behav-
iour seen in mice may be the result of hypothalamic dysfunction [66]. In the same study patients
with HD had increased thirst, unaffected urine osmolality and increased serum vasopressin, sug-
gesting a dysregulation in the control of hypothalamic vasopressin release [66]. In another trans-
genic mouse model the hypothalamic expression of vasopressin was down-regulated without
observing a significant loss of hypothalamic neurons [84]. In our study there was no significant
difference in the fasting levels of plasma vasopressin levels between premanifest HD, stage II/III
HD patients and controls. There are several differences between our study and that of Wood et al
[66] that could account for this difference: 1. vasopressin levels differ in serum and plasma; 2.
Wood et al included patients taking medication that may influence hormone levels; 3. Since vaso-
pressin has a circadian rhythm [85], levels observed will depend on time of sampling: our sam-
pling time was at 06:00 hours, whereas the sampling time in the Wood et al study was in the
afternoon between 14:00–17:00 [66]; 4. Since hypoglycaemia causes the release of vasopressin
[86], the fasting status may also have an effect on the levels of vasopressin.
Somatotropic axis
Studies analysing GH concentration in HD have yielded conflicting results with four studies
reporting no significant difference between HD patients and controls [87–90], and three
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studies reporting an increase in HD [24,25,91]. GH exerts its effects by stimulating IGF-1
release from the liver. Saleh et al [24] have reported an increase in both central (GH) and periph-
eral (IGF-1) somatotropic hormones in early HD patients compared to healthy controls, as well
as increase with disease severity. The study included a large cohort of patients (n = 217), but only
a single morning sample in the morning was analysed and the cohorts were not controlled for
medication (56% patients used neuroleptics, 61% antidepressants, 37% tranquillizers) [24]. This
is important since neuroleptic treatment can influence GH levels by altering dopaminergic regu-
lation [92]. Our study excluded patients using neuroleptics in the preceding 6 months.
Phillipson et al [25] also reported elevated fasting plasma GH levels in HD patients compared
to controls. In our study, we found no significant difference in morning, fasting levels of GH or
IGF-1, which is in agreement to several previous studies [87–90]. In a 24-hour study of plasma
GH concentration in female HD patients free from centrally-active medication andmatched con-
trols, Durso et al showed increased levels of GH in HD females throughout the 24-hour period
[91], which is in contrast to our findings. However, it is known in women that the amplitude of
GH secretory pulses correlate with circulating levels of oestradiol [93,94]. In our study many of
the female subjects had low oestradiol levels, which may lead to the low GH concentrations. In
addition, in menstruating women, 24-hour GH levels are higher compared to age-matched men
[93]. Thus, since in our study we had both males and females, this may account for the lower lev-
els of GH observed compared to the Durso et al study [91]. However, when we analyse the female
data separately, we still do not see an increase in GH levels in HD patients.
In this study we observed lower concentrations of 24 hour and post-sleep GH in stage II/III
HD patients but these were not significant. Potentially, a study of larger cohorts may verify
whether this is a biologically significant observation. Decreased concentrations of post-sleep
GH in premanifest and stage II/III HD subjects may be indicate delay in sleep onset since GH
secretion in early sleep is temporally and quantitatively associated with the amount of slow
wave sleep [95,96]. Transient awakenings during sleep inhibit GH release [97], suggesting the
decrease in nocturnal GH levels in HD subjects are secondary to fragmented sleep. GHRH
inhibits sleep as well as GH secretion [98], thus if decreased GH levels in the HD subjects are
associated with sleep delay, one would expect GHRH release to also be lower. We did not
observe any change in GHRH levels, but this did not include measurement of post-sleep levels.
The normality of GHRH levels at 06:00, 15:00 and 23:00 is in keeping with the finding of no
significant difference on GH concentration at these time points.
IGF-1 decreases GH release from the pituitary by negative feedback, implying that low post-
sleep GH levels in HD subjects would be associated with higher IGF-1 levels. The relationship
between IGF-1 and GHmay be better reflected by the ratio of the two in serum at any particu-
lar time and analysis of our data showed a higher IGF-1:GH ratio in stage II/III HD patients at
23.00 but this was not statistically significant. Further studies examining sleep quality in HD
patients and measuring levels of GHRH and IGF-1, in parallel with GH in larger groups may
be helpful. Another reason for possible reduction in sleep-related GH levels in HD gene carri-
ers may be linked to a reduction in the night-time melatonin release we observed in these
cohorts [99], since it has been shown that melatonin administration increases basal GH release
and GH responsiveness to GHRH, possibly by inhibiting endogenous somatostatin release at
the hypothalamic level [100,101].
Gonadotropic axis
In men with HD, reduced testosterone concentrations linked to disease severity have been
reported [24,44]. In R6/2 mice, reduced testosterone is found and is accompanied by a reduc-
tion of gonadotropin releasing hormone (GnRH) neurons in the hypothalamus, suggesting this
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may be secondary to hypothalamic dysfunction [42]. In contrast, YAC128 mice develop testic-
ular degeneration before levels of testosterone decrease and before loss of GnRH neurons in
the hypothalamus can be detected, suggesting that testicular pathology results from a direct
toxic effect of mutant huntingtin in the testes [43]. In contrast to previous studies, we did not
observe an alteration in testosterone levels in HD males, nor in the levels of LH, FSH or oestra-
diol. The studies that reported lower testosterone levels in HD [24,44] included patients at dif-
ferent disease stages (TFC 0–13, and motor score 1–110), whereas, in our study, we had a
mixture of premanifest and stage II/III HD subjects (TFC 5–13 and motor score 0–65).
To date, only two studies have analysed LH and FSH levels in male HD patients [24,44].
Both studies found no significant difference in FSH levels between control and HDmales
[24,44], which is in agreement with our data. Saleh et al found no significant difference in fast-
ing, morning levels of LH [24], whereas Markianos et al reported lower LH levels in HD males
in samples obtained between 10:00 and 12:00 [44]. We found no significant difference in LH
levels between HD and control subjects (males or females) over 24 hours.
Gonadotropic axis hormones have not been carefully investigated in female HD patients. In
our study, information on menopausal and menstrual cycle phase at the time of blood sam-
pling for was available. We observed increased LH and FSH levels in pre- and post-menopausal
women compared to other females, however, there was no significant difference between HD
females and control females. More detailed study of gonadotrophic hormones at different
phases of the menstrual cycle are needed to properly evaluate whether these hormones are
altered in females with HD.
In the current study the only significant difference found in the gonadotropic axis was in
fasting DHEAS levels, where a significant reduction could be seen in stage II/III patients with
HD. This is in agreement with two previous studies that reported reduced DHEAS levels in
HD patients [21,23]. Here, DHEAS was measured at only one timepoint, thus, measuring the
circadian rhythm of DHEAS may be of interest. We also observed a non-significant reduction
in DHEAS levels with increasing disease burden. DHEAS should ideally be analysed separately
in males and females [102], however, we do not have a high number of subjects and when ana-
lysed separately for males and females, DHEAS levels are lower in HD gene carriers, however
this is not statistically significant.
Lactotropic axis
Politis et al 2008 demonstrated D2 receptor loss in the hypothalamus of both early-stage HD
patients and premanifest HD mutation carriers [63]. D2 receptors stimulation inhibits prolac-
tin release [103]. Prolactin levels in patients with HD have been reported to be unchanged
[24,39,41,87–89,91], increased [67,104] or even decreased [105,106]. In a 24-hour study with 6
medication-free male patients, Aziz et al (2010) demonstrated that prolactin secretion tended
to be non-significantly higher in HD patients and significantly more irregular[39]. In our study
we did not detect any significant difference in fasting prolactin levels between control and HD
individuals. To date it remains unclear whether the lactotropic axis is indeed affected in HD.
Prolactin rhythmicity is primarily regulated by the sleep-wake cycle and maximal secretion
occurs when sleep and circadian effects are superimposed [107–109]. Like GH, increased pro-
lactin secretion is temporally associated with slow wave sleep and fragmented sleep results in
decreased prolactin levels [110].
Thyrotropic axis
Progressive weight loss and muscle wasting are common in HD patients [14–16,111–114].
Since the thyrotropic axis is involved in the regulation of body weight and metabolism [38],
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several studies have evaluated hypothalamic-pituitary-thyroid axis function in patients with
HD. Many studies have shown similar levels of TSH, total T4, T3 and free T4 in HD patients
and normal controls [24,39–41,88]. However, in a retrospective study of HD patients, levothyr-
oxine was found to be the most commonly prescribed drug for problems ‘unrelated’ to HD
[115].
Although TSH synthesis and secretion are primarily controlled by the stimulatory action of
thyrotropin-releasing hormone (TRH) and the negative feedback by thyroid hormones, other
factors such as dopamine exert important modulatory effects [38]. Dopamine inhibits TSH
synthesis and release through D2 receptor activation, whereas it stimulates TRH secretion [38].
One study showed similar TSH and T4 levels but higher T3 levels in early HD subjects
which were not significantly increased compared with healthy controls [39]. Our findings do
not support mild thyrotropic axis hyperactivity in HD but indicate a more focussed analysis in
a larger cohort is warranted.
Since we only measured TSH at one time-point in the morning, we do not know whether its
circadian rhythmicity is affected in HD subjects since TSH levels are low and relatively stable
throughout the daytime and begin to increase in the early evening, with maximal levels around
the beginning of the sleep period [116]. TSH levels progressively decline during the latter part of
sleep, and this decrease is associated with slow wave sleep, while awakening result in increased
TSH levels [117–119]. It has been suggested that the TSH evening rise shifts in concordance with
the melatonin rhythm [120] and since we observed a reduction in the night-time melatonin in
our HD cohorts [99], it is possible that TSH rhythm is also affected. Also, since the fT3 diurnal
rhythm parallels TSH variations [121], the fT3 rhythmicity may also be altered in HD.
Correlation with clinical measures
It has previously been shown in a longitudinal study that IGF-1 correlates with cognitive mea-
sures: Stroop Word Reading, Stroop Colour Naming, Symbol Digit Modalities Test and Verbal
Fluency [122]. We did not observe significant correlations between IGF-1 and any of these cog-
nitive measures. Although the correlations in our study were not significant, they were all nega-
tive. This may reflect a true biological finding although may also reflect low number of HD
subjects in our study. Thus, a longitudinal follow-up of our patients is needed to elucidate
whether high IGF-1 levels correlate with poor cognition.
Conclusion
In contrast to many previous studies we describe overwhelmingly negative results, with no sta-
tistically significant differences. This may in part be down to small sample sizes and resulting
low statistical power to find moderately sized differences. However, this lack of significant dif-
ferences may also reflect the strict inclusion criteria, excluding patients on medication which is
anticipated to alter these pathways (and perhaps, as a result, excluding some of the more
severely affected HD patients). Our results are at least suggestive that with our patient inclusion
criteria, there are differences of any appreciable size in not more than a small proportion of
these biological markers, since even in the absence of any such associations a few significant
results could readily have been found. We found only very subtle non-significant differences in
hypothalamic-pituitary hormones in HD subjects, (e.g. decreased post-sleep GH and fasting
DHEAS) that may warrant study in larger controlled cohorts.
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